<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Temozolomide Resistance &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/temozolomide-resistance/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 10 Jan 2026 11:32:27 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Temozolomide Resistance &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>HDAC1 Condensation Links to Temozolomide Response in Glioblastoma</title>
		<link>https://bioengineer.org/hdac1-condensation-links-to-temozolomide-response-in-glioblastoma/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 10 Jan 2026 11:32:21 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[and therapeutic implications]]></category>
		<category><![CDATA[Based on the content focusing on the molecular mechanism of temozolomide resistance involving HDAC1 condensation]]></category>
		<category><![CDATA[HDAC1 condensation]]></category>
		<category><![CDATA[here are 5 appropriate tags: **Glioblastoma]]></category>
		<category><![CDATA[phase separation]]></category>
		<category><![CDATA[Targeted therapy** **Reasoning:** 1. **Glioblastoma:** The primary cancer type studied. 2. **Temozolomide resistance:** The core clinical problem being addressed. 3. **]]></category>
		<category><![CDATA[Temozolomide Resistance]]></category>
		<guid isPermaLink="false">https://bioengineer.org/hdac1-condensation-links-to-temozolomide-response-in-glioblastoma/</guid>

					<description><![CDATA[In the ongoing battle against glioblastoma, one of the most aggressive forms of brain cancer, the standard therapy temozolomide has been a beacon of hope. However, this hope is often tempered by the unfortunate reality that patients who initially respond well to the drug may later experience a significant decline in its efficacy. This phenomenon, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">315645</post-id>	</item>
		<item>
		<title>PRMT6 Boosts Temozolomide Resistance in Glioblastoma</title>
		<link>https://bioengineer.org/prmt6-boosts-temozolomide-resistance-in-glioblastoma/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 04 Jan 2026 14:15:38 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Chemoresistance** * **Glioblastoma:** Makalenin temel konusu. * **PRMT6:** Araştırmanın ana odağı ve keşfedilen kilit protein. * **Temozolomide Resistance:** Çalış]]></category>
		<category><![CDATA[hypoxia]]></category>
		<category><![CDATA[Makale içeriğine ve anahtar kelimelere göre en uygun 5 etiket: **Glioblastoma]]></category>
		<category><![CDATA[PRMT6]]></category>
		<category><![CDATA[Temozolomide Resistance]]></category>
		<guid isPermaLink="false">https://bioengineer.org/prmt6-boosts-temozolomide-resistance-in-glioblastoma/</guid>

					<description><![CDATA[Recent advances in cancer research have uncovered a startling mechanism behind the resistance of glioblastoma multiforme (GBM) to the chemotherapeutic agent temozolomide (TMZ). The pivotal role of hypoxia in tumor progression has long been recognized, yet the specific molecular pathways that are activated under these conditions have remained elusive. In a breakthrough study conducted by [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">313562</post-id>	</item>
	</channel>
</rss>
